

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.\***

*(a joint stock limited company established in the People's Republic of China with limited liability)*

**(Stock Code: 8058)**

### **ANNOUNCEMENT POLL RESULTS OF THE ANNUAL GENERAL MEETING**

The Board is pleased to announce that the resolutions as set out in the Notice (as defined below) dated 6 May 2016 were duly passed at the AGM held on 22 June 2016.

#### **POLL RESULTS OF THE AGM**

References are made to the notice of AGM (the “**Notice**”) of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (the “**Company**”) dated 6 May 2016. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the Notice.

The Board is pleased to announce that the resolutions as set out in the Notice dated 6 May 2016 were duly passed by way of poll at the AGM which was held at Conference Room, Level 3, Administrative Centre, Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province, PRC on 22 June 2016.

As at the date of the AGM, the Company had issued a total of 609,600,000 Shares, comprising 164,560,000 H Shares and 445,040,000 Domestic Shares. The total number of Shares entitling the Shareholders to attend and vote for or against the resolutions at the AGM was 609,600,000 Shares.

\* *For identification purpose only*

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolution at the AGM as set out in Rule 17.47A of the GEM Listing Rules and there were no Shares requiring the Shareholders to abstain from voting at the AGM under the GEM Listing Rules.

Hodgson Impey Cheng Limited (國衛會計師事務所有限公司) was appointed as scrutineer for the vote-taking at the AGM.

## THE AGM

At the AGM, Shareholders or their proxies holding 582,609,626 Shares with voting right, representing 95.57 % of the entire issued share capital of the Company, were present and constituted a quorum for the AGM in accordance with the articles of association of the Company and the Company Law of the PRC.

The Board is pleased to announce that the resolutions as set out in the AGM Notice were duly passed at the AGM, the poll results of which are as follows:

Ordinary resolutions		Number of Votes Cast (%)	
		For	Against
1.	to consider and approve the audited financial statements of the Company and the reports of the board (the “ <b>Board</b> ”) of directors (the “ <b>Directors</b> ”) and the auditors of the Company for the year ended 31 December 2015;	582,609,626 (100%)	0 (0%)
2.	to consider and approve the report of the supervisors of the Company for the year ended 31 December 2015;	582,609,626 (100%)	0 (0%)
3.	to consider and approve a final dividend of RMB0.35 per share for the year ended 31 December 2015;	582,609,626 (100%)	0 (0%)
4.	to consider and approve the Board to fix the remunerations of the Directors and supervisors of the Company;	582,431,626 (99.97%)	178,000 (0.03%)
5.	to consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration;	582,609,626 (100%)	0 (0%)

Ordinary resolutions		Number of Votes Cast (%)	
		For	Against
6.	to re-elect Mr. Liu Baoqi (劉保起) as an executive Director;	582,609,626 (100%)	0 (0%)
7.	to re-elect Ms. Li Minghua (李明華) as an executive Director;	582,609,626 (100%)	0 (0%)
8.	to re-elect Mr. Han Fengsheng (韓風生) as an executive Director;	582,609,626 (100%)	0 (0%)
9.	to re-elect Mr. Chen Yu (陳雨) as an executive Director;	582,609,626 (100%)	0 (0%)
10.	to re-elect Mr. Liu Zhenteng (劉振騰) as an executive Director;	582,609,626 (100%)	0 (0%)
11.	to re-elect Mr. Liu Zhenhai (劉振海) as a non-executive Director;	577,065,591 (99.05%)	5,544,035 (0.95%)
12.	to re-elect Mr. Foo Tin Chung (傅天忠) as an independent non-executive Director;	580,100,333 (99.57%)	2,509,293 (0.43%)
13.	to re-elect Mr. Fu Hongzheng (付宏征) as an independent non-executive Director;	582,609,626 (100%)	0 (0%)
14.	to re-elect Prof. Du Guanhua (杜冠華) as an independent non-executive Director;	580,100,333 (99.57%)	2,509,293 (0.43%)
15.	to appoint Ms. Huang Huiwen (黃慧文) as an independent non-executive Director;	582,609,626 (100%)	0 (0%)
16.	to re-elect Mr. Wang Jian (王健) as a supervisor; and	580,724,333 (99.68%)	1,885,293 (0.32%)
17.	to re-elect Mr. Liu Zhenfei (劉振飛) as a supervisor.	580,724,333 (99.68%)	1,885,293 (0.32%)

As more than one-half of the votes were cast in favour of each of the resolution at the AGM, all resolutions as set out in the AGM Notice were duly passed as ordinary resolutions of the Company.

By order of the Board  
**Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.\***  
**Liu Baoqi**  
*Chairman*

PRC, 22 June 2016

*As at the date of this announcement, the Board comprises 11 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors; Mr. Yin Chuangui (尹傳貴) and Mr. Liu Zhenhai (劉振海) are non-executive Directors; and Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Chen Yun Zhen (陳允震) and Prof. Du Guanhua (杜冠華) are independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from its date of publication and on the Company’s designated website at: <http://shandongluoxin.quamir.com>.*

\* *English names are translated for identification purposes only*